Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Methimazole

2

X.s Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

1
Last update : 30/08/2012
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist

Publications

Systemic p-ANCA vasculitis with fatal outcome, arising in the setting of methimazole use.
Clinical nephrology. Case studies 2019;7;23-26 2019
Antineutrophilic Cytoplasmic Antibody Positive Vasculitis Associated with Methimazole Use.
Case reports in endocrinology 2015;2015;530319 2015
PTU-induced ANCA-positive vasculitis: an innocent or a life-threatening adverse effect?
Rheumatology international 2013 Jan;33;117-20 2013 Jan
ANCA-associated vasculitis with central retinal artery occlusion developing during treatment with methimazole.
Internal medicine (Tokyo, Japan) 2012;51;3177-80 2012
Antineutrophil cytoplasmic antibody-positive vasculitis in a patient with graves disease: cross-reaction between propylthiouracil and methimazole.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2010;16;449-51 2010
Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: comparison with idiopathic ANCA vasculitides.
Arthritis research & therapy 2005;7;R1072-81 2005

Powered by

  • ^
  • Contact
  • Cookies
  • About